MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Entry into a Material Definitive AgreementItem 1.01.
(d) Exhibits
|
Exhibit No. |
Description |
| 1.1 | Underwriting Agreement, dated February7, 2018, between MediciNova, Inc. and Ladenburg Thalmann& Co. Inc. |
| 5.1 | Opinion and Consent of Gunderson Dettmer Stough Villeneuve Franklin& Hachigian, LLP |
| 23.1 | Consent of Gunderson Dettmer Stough Villeneuve Franklin& Hachigian, LLP (included in Exhibit 5.1) |
| 99.1 | Press release issued by MediciNova, Inc. dated February7, 2018 titled “MediciNova Announces Proposed Underwritten Public Offering of Common Stock” |
| 99.2 | Press release issued by MediciNova, Inc. dated February7, 2018 titled “MediciNova Announces Pricing of Underwritten Public Offering of Common Stock” |
MEDICINOVA INC ExhibitEX-1.1 2 d439817dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version MEDICINOVA,…To view the full exhibit click here
About MEDICINOVA, INC. (NASDAQ:MNOV)
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its MN-166 is an oral, anti-inflammatory and neuroprotective agent, which inhibits macrophage migration inhibitory factor (MIF) and certain phosphodiesterases (PDEs). Its MN-001 is an orally bioavailable small molecule compound. Its MN-221 is a highly selective B2-adrenergic receptor agonist being developed for the treatment of acute exacerbations of asthma.